Mibolic

Copper Tetramibi Tetrafluoroborate, the active ingredient in Mibolic, is a chemical compound presented as an injectable solution for intravenous use. It is being evaluated for potential therapeutic applications in clinical research settings. GNH USA supplies Mibolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mibolic (Copper Tetramibi Tetrafluoroborate) is currently investigated in clinical research, primarily within infectious disease and oncology domains.

Investigational Use: evaluated for potential antimicrobial activity Preclinical Studies: used to explore copper‑dependent biochemical pathways Pharmacokinetic Research: employed to assess distribution and clearance of copper complexes

Adverse reactions reported for intravenous copper complexes vary in frequency and severity.

Common Side Effects: - Infusion site pain or irritation - Mild nausea or vomiting - Transient headache - Flushing or warmth sensation - Mild hypotension - Low‑grade fever

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension or shock - Acute renal impairment - Hepatic toxicity - Cardiac arrhythmias - Copper overload leading to neurologic symptoms

When handling Mibolic, consider the following safety measures.

Assess renal function: evaluate baseline kidney parameters before infusion Monitor serum copper levels: periodic testing to detect accumulation Avoid in known hypersensitivity: discontinue if allergic reaction occurs Use with caution in hepatic impairment: adjust monitoring frequency Observe for infusion reactions: be prepared to manage acute events Store at ambient temperature: keep in original container, protect from moisture and light

Potential drug interactions with copper‑based intravenous agents should be reviewed.

Major Interactions (Avoid): - Concurrent copper supplements: risk of copper toxicity - Strong chelating agents (e.g., penicillamine): may reduce drug efficacy

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs: monitor renal function closely - Antihypertensives: possible additive hypotensive effect - Other IV electrolytes: watch for electrolyte imbalance